Related Experiment Video
Updated: Jul 29, 2025
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Lipid-Based Inhalable Micro- and Nanocarriers of Active Agents for Treating Non-Small-Cell Lung Cancer
1Department of Chemistry, School of Basic & Applied Sciences, Galgotias University, Greater Noida 203201, India.
Abstract:
Non-small-cell lung cancer (NSCLC) afflicts about 2 million people worldwide, with both genetic (familial) and environmental factors contributing to its development and spread. The inadequacy of currently available therapeutic techniques, such as surgery, chemotherapy, and radiation therapy, in addressing NSCLC is reflected in the very low survival rate of this disease. Therefore, newer approaches and combination therapy regimens are required to reverse this dismal scenario. Direct administration of inhalable nanotherapeutic agents to the cancer sites can potentially lead to optimal drug use, negligible side effects, and high therapeutic gain. Lipid-based nanoparticles are ideal agents for inhalable delivery owing to their high drug loading, ideal physical traits, sustained drug release, and biocompatibility. Drugs loaded within several lipid-based nanoformulations, such as liposomes, solid-lipid nanoparticles, lipid-based micelles, etc., have been developed as both aqueous dispersed formulations as well as dry-powder formulations for inhalable delivery in NSCLC models in vitro and in vivo. This review chronicles such developments and charts the future prospects of such nanoformulations in the treatment of NSCLC.
Insights
Inhalable nanotherapeutics offer a promising new approach for treating non-small-cell lung cancer (NSCLC). Lipid-based nanoparticles improve drug delivery, potentially increasing effectiveness and reducing side effects for NSCLC patients.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Non-small-cell lung cancer (NSCLC) affects millions globally, with current treatments showing limited efficacy.
- Existing therapies like surgery, chemotherapy, and radiation have low survival rates for NSCLC.
- Novel therapeutic strategies are crucial for improving outcomes in NSCLC treatment.
Purpose of the Study:
- To review the development of inhalable nanotherapeutics for non-small-cell lung cancer (NSCLC).
- To explore the potential of lipid-based nanoparticles in delivering drugs directly to lung cancer sites.
- To discuss the advantages and future prospects of nanoformulations in NSCLC therapy.
Main Methods:
- Review of existing literature on inhalable nanotherapeutics for NSCLC.
- Focus on lipid-based nanoparticles (liposomes, solid lipid nanoparticles, micelles).
- Analysis of both in vitro and in vivo studies using nanoformulations for NSCLC models.
Main Results:
- Inhalable nanotherapeutics can enable direct drug administration to NSCLC sites.
- Lipid-based nanoparticles demonstrate high drug loading, sustained release, and biocompatibility.
- Various lipid-based nanoformulations have been developed for inhalable NSCLC treatment.
Conclusions:
- Inhalable lipid-based nanotherapeutics present a promising strategy for NSCLC treatment.
- These nanoformulations offer potential for improved drug utilization and reduced side effects.
- Further research and development in this area could significantly advance NSCLC therapy.
Related Concept Videos
01:23Inhaled Medications
01:22Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...